Moderna Appoints Juan Andres as Chief Operating Officer; Jerh Collins to Retire

Executive Appointment and Departure Summary

On September 30, 2026, Moderna, Inc. reported under Item 5.02 of Form 8-K the creation of a new Chief Operating Officer (COO) role and executive leadership transitions:

1. Appointment of Chief Operating Officer:

   • Executive: Juan Andres (age 62)
   • Effective Date: October 5, 2026
   • Reporting Structure: Reports directly to CEO Stéphane Bancel and will serve on the Executive Committee.
   • Background: Andres previously spent nearly six years at Moderna, serving as Chief Technical Operations and Quality Officer (2018–2022) and President of Strategic Partnerships and Enterprise Expansion before retiring in 2023. His return is positioned to support operations and manufacturing scale-up, notably for intismeran autogene and oncology expansion.

2. Compensation Arrangements:

   • Base Salary: $800,000 per year.
   • Target Cash Incentive: 90% of base salary (prorated for 2026).
   • New Hire Equity Grant: Equity award with a target value of $5,000,000 subject to four-year vesting, deliverable as a mix of non-qualified stock options and/or RSUs (RSUs capped at 75%).
   • Future Annual Equity: Annual equity target between $4,000,000 and $5,000,000.
   • Severance & Indemnification: Participation in Moderna's Amended and Restated Executive Severance Plan and standard executive indemnification.

3. Executive Retirement:

   • Executive: Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, announced his retirement after four years with the Company.

Strategic and Market Context

The COO role comes as Moderna expands its manufacturing footprint and prepares for commercial scale-up of its oncology portfolio following Phase 3 results for intismeran autogene, alongside continued franchise development in respiratory combination vaccines.